ArticleInternational journal of cancer2011
Bioactive tanshinones in Salvia miltiorrhiza inhibit the growth of prostate cancer cells in vitro and in mice.
Article in International journal of cancer, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 124 citations in OpenAlex.
- Targeting RSF1 with tanshinone I inhibits cervical cancer cell growth through modulation of NF-κB pathway.Frontiers in pharmacology · 2026Article
- Tanshinones target drug-resistant tuberculosis: efficacy, selectivity, and potential mechanism of action.RSC medicinal chemistry · 2025Article
- Aurora kinases signaling in cancer: from molecular perception to targeted therapies.Molecular cancer · 2025Review
- An Ethnopharmacological Survey on Medicinally Important Plants of Genus Salvia.Combinatorial chemistry & high throughput screening · 2025Review
- Effects of Fermentation with Kombucha Symbiotic Culture of Bacteria and Yeasts on Antioxidant Activities, Bioactive Compounds and Sensory Indicators ofMolecules (Basel, Switzerland) · 2024Article
- A review of tanshinone compounds in prostate cancer treatment.Translational andrology and urology · 2024Review
- Natural STAT3 Inhibitors for Cancer Treatment: A Comprehensive Literature Review.Recent patents on anti-cancer drug discovery · 2024Review
- Advanced application of nanotechnology in active constituents of Traditional Chinese Medicines.Journal of nanobiotechnology · 2023Review
- Natural Compounds ofBiomedicines · 2023Review
- Tanshinone IIA targeting cell signaling pathways: a plausible paradigm for cancer therapy.Pharmacological reports : PR · 2023Review
- Epigenetic effects of herbal medicine.Clinical epigenetics · 2023Review
- Neuroprotective Effects of Geopung-Chunghyuldan Based on Its Salvianolic Acid B Content Using an In Vivo Stroke Model.Current issues in molecular biology · 2023Article
- Molecular Mechanism of Tanshinone against Prostate Cancer.Molecules (Basel, Switzerland) · 2022Review
- Dihydrotanshinone I Enhances Cell Adhesion and Inhibits Cell Migration in Osteosarcoma U-2 OS Cells through CD44 and Chemokine Signaling.Molecules (Basel, Switzerland) · 2022Article
- Research and Development of Natural Product Tanshinone I: Pharmacology, Total Synthesis, and Structure Modifications.Frontiers in pharmacology · 2022Review
- Assessing the protective effects of cryptotanshinone on CoClMolecular medicine reports · 2021Article
- Article
- Article
- Article
- Tanshinone IIA: A Review of its Anticancer Effects.Frontiers in pharmacology · 2020Review
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Searching for efficacious and safe agents for the chemoprevention and therapy of prostate cancer has become the top priority of research. The objective of this study was to determine the effects of a group of tanshinones from a Chinese herb Salvia Miltiorrhiza, cryptotanshinone (CT), tanshinone IIA (T2A) and tanshinone I (T1) on prostate cancer. The in vitro studies showed that these tanshinones inhibited the growth of human prostate cancer cell lines in a dose-dependent manner via cell cycle arrest and apoptosis induction. Among three compounds, T1 had the most potent activity with IC(50) s around 3-6 μM. On the other hand, tanshinones had much less adverse effects on the growth of normal prostate epithelial cells. The epigenetic pathway focused array assay identified Aurora A kinase as a possible target of tanshinone actions. The expression of Aurora A was overexpressed in prostate cancer cell lines. Moreover, knockdown of Aurora A in prostate cancer cells significantly decreased cell growth. Tanshinones significantly downregulated the Aurora A expression, suggesting Aurora A may be a functional target of tanshinones. Tanshinones, especially T1, also showed potent anti-angiogenesis activity in vitro and in vivo. Furthermore, T1 inhibited the growth of DU145 prostate tumor in mice associated with induction of apoptosis, decrease of proliferation, inhibition of angiogenesis and downregulation of Aurora A, whereas it did not alter food intake or body weight. Our results support that T1 may be an efficacious and safe chemopreventive or therapeutic agent against prostate cancer progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.